Lurasidone

The dosage of lurasidone must be individualized based on the condition being treated and the patient's clinical response. Healthcare providers typically start with a lower dose and gradually increase it (titration) to find the most effective and tolerable amount.

• Schizophrenia: The recommended starting dose is 40 mg once daily. Clinical studies indicate that doses ranging from 40 mg to 160 mg per day are effective. The maximum recommended dose for schizophrenia is 160 mg per day.
• Bipolar Depression: The recommended starting dose is 20 mg once daily. The dose can be increased up to 120 mg per day if necessary. Interestingly, clinical trials for bipolar depression did not show that higher doses (80-120 mg) were significantly more effective than lower doses (20-60 mg), but some individual patients may require the higher range.

Lurasidone is approved for use in specific pediatric populations, but strict age limits apply.

• Schizophrenia (Ages 13-17): The starting dose is 40 mg once daily, with a target range of 40 mg to 80 mg per day. The maximum dose for adolescents is 80 mg per day.
• Bipolar Depression (Ages 10-17): The starting dose is 20 mg once daily. The recommended dose range is 20 mg to 80 mg per day.
• Safety Note: Lurasidone has not been studied and is not recommended for children under the age of 10 for bipolar depression or under 13 for schizophrenia.

Certain medical conditions change how the body processes lurasidone, requiring dosage modifications to prevent toxicity.

Renal Impairment

For patients with moderate to severe renal (kidney) impairment (creatinine clearance < 50 mL/min), the starting dose should not exceed 20 mg, and the maximum dose should be capped at 80 mg per day. No adjustment is typically needed for mild renal impairment.

Hepatic Impairment

For patients with moderate hepatic (liver) impairment (Child-Pugh Score 7 to 9), the starting dose is 20 mg with a maximum of 80 mg. For those with severe hepatic impairment (Child-Pugh Score 10 to 15), the maximum dose is restricted to 40 mg per day.

Elderly Patients

While no specific dose adjustment is universally required for the elderly based solely on age, healthcare providers often start at the lower end of the dosing range due to the higher frequency of decreased hepatic, renal, or cardiac function in this population.

To ensure the medication is absorbed correctly and works as intended, patients must follow these specific administration rules:

1. 1The 350-Calorie Rule: Lurasidone must be taken with food. A meal or snack containing at least 350 calories is required. If taken on an empty stomach, the medication will not be absorbed properly, and it may not be effective. The type of food (fat vs. protein) is less important than the total calorie count.
2. 2Consistency: Take the medication at the same time every day to maintain steady levels in your bloodstream.
3. 3Swallow Whole: Tablets should be swallowed whole. Do not crush, chew, or break the tablets unless specifically instructed by your doctor, as this can affect how the drug is released.
4. 4Storage: Store the medication at room temperature (68°F to 77°F) in a dry place away from moisture and light.

If you miss a dose of lurasidone, take it as soon as you remember, provided you can take it with the required 350 calories of food. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Never 'double up' on doses to make up for a missed one, as this increases the risk of serious side effects.

Signs of a lurasidone overdose may include extreme drowsiness, rapid heartbeat (tachycardia), seizures, or uncontrollable muscle movements. Because lurasidone is highly protein-bound, dialysis is not effective in removing it from the system. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Provide the medical team with the exact time of ingestion and the estimated amount taken.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as sudden discontinuation can lead to a return of psychiatric symptoms.

Most patients taking lurasidone will experience at least one mild to moderate side effect. These often occur during the first few weeks of treatment as the body adjusts to the medication.

• Somnolence (Drowsiness): This is one of the most frequently reported side effects. It can range from mild tiredness to a heavy feeling of sedation. Taking the medication at night may help manage this.
• Akathisia: This is a specific type of movement disorder characterized by an inner sense of restlessness and an urgent need to move. Patients often describe it as 'feeling like I'm jumping out of my skin' or being unable to sit still.
• Nausea: Feeling sick to the stomach is common, especially when starting the medication. Because lurasidone must be taken with food, the meal itself may help mitigate some of the nausea.
• Extrapyramidal Symptoms (EPS): This refers to various movement issues, including muscle stiffness, tremors, or slow movements (bradykinesia).

• Insomnia: Some patients may find it difficult to fall or stay asleep.
• Vomiting: More severe than simple nausea, this may require a dose adjustment.
• Increased Salivation: A noticeable increase in saliva production or drooling.
• Dystonia: Sudden, involuntary muscle contractions, often in the neck, jaw, or tongue.
• Weight Gain: While lurasidone is considered 'weight-neutral' compared to other antipsychotics, some patients may still experience a modest increase in weight.

• Hyperprolactinemia: An increase in the hormone prolactin, which can lead to breast swelling, nipple discharge, or changes in menstrual periods.
• Dyslipidemia: Changes in cholesterol or triglyceride levels.
• Tardive Dyskinesia (TD): A potentially irreversible condition involving repetitive, involuntary movements, typically of the face, tongue, or jaw. The risk of TD increases with the duration of treatment and the cumulative dose.

> Warning: Stop taking Lurasidone and call your doctor immediately if you experience any of these serious reactions.

• Neuroleptic Malignant Syndrome (NMS): A rare but life-threatening reaction characterized by high fever, stiff muscles, confusion, sweating, and changes in heart rate or blood pressure. This is a medical emergency.
• Severe Allergic Reactions: Symptoms include rash, itching, hives, and swelling of the face, lips, or throat (angioedema).
• Seizures: Lurasidone can lower the seizure threshold, especially in patients with a history of epilepsy.
• High Blood Sugar (Hyperglycemia): In extreme cases, this can lead to ketoacidosis or coma. Symptoms include extreme thirst, frequent urination, and fruity-smelling breath.
• Low White Blood Cell Count: A significant drop in infection-fighting cells (leukopenia or neutropenia) can occur, making you more susceptible to infections.

With prolonged use, patients should be monitored for metabolic changes. Although lurasidone has a lower risk than some other medications, long-term use can still contribute to the development of Type 2 Diabetes or cardiovascular issues. Regular monitoring of weight, blood glucose, and lipid profiles is recommended. Additionally, the risk of Tardive Dyskinesia is a primary concern with long-term antipsychotic therapy; healthcare providers should perform regular 'AIMS' (Abnormal Involuntary Movement Scale) exams to catch early signs of this condition.

Lurasidone carries two critical FDA Black Box Warnings—the most serious type of warning issued by the FDA.

1. 1Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lurasidone is not approved for the treatment of patients with dementia-related psychosis.
2. 2Suicidal Thoughts and Behaviors: Antidepressants and some antipsychotics used for depression can increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24). Patients of all ages starting lurasidone for bipolar depression should be monitored closely for worsening of symptoms or the emergence of suicidal ideation.

Report any unusual symptoms or changes in mood to your healthcare provider immediately.

Lurasidone is a powerful psychiatric medication that requires careful medical supervision. It is essential that patients understand that this medication does not cure schizophrenia or bipolar disorder; rather, it helps manage the symptoms. Treatment should never be stopped abruptly, as this can lead to a rapid return of symptoms or withdrawal-like effects.

The FDA has mandated the following Black Box Warnings for lurasidone:

• Dementia-Related Psychosis: There is an increased risk of death in elderly patients with dementia who take antipsychotics. Most deaths appear to be cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.
• Suicidality: In clinical trials of patients with bipolar depression, there was an observed increase in suicidal thinking and behavior in pediatric and young adult patients. Families and caregivers should be alert to daily changes in mood, behavior, or signs of agitation.

• Cerebrovascular Adverse Reactions: In clinical trials of elderly patients with dementia, there was a higher incidence of stroke and transient ischemic attacks (TIAs) in those taking antipsychotics.
• Neuroleptic Malignant Syndrome (NMS): This is a potentially fatal symptom complex. If a patient develops high fever and muscle rigidity, the medication must be discontinued immediately.
• Tardive Dyskinesia: The risk of developing involuntary movements increases with the length of treatment. If signs of TD appear, the healthcare provider may consider stopping the medication.
• Metabolic Changes: Atypical antipsychotics are associated with metabolic changes, including high blood sugar (hyperglycemia), high cholesterol (dyslipidemia), and weight gain. Regular blood tests are required.
• Orthostatic Hypotension and Syncope: Lurasidone may cause a sudden drop in blood pressure when standing up, which can lead to dizziness or fainting. This is most common when first starting the drug or increasing the dose.
• Hyperprolactinemia: Like other D2 antagonists, lurasidone can elevate prolactin levels, which may affect reproductive function and bone density over time.

To ensure safety, your healthcare provider will likely require the following tests:

• Blood Glucose: To monitor for the development of diabetes.
• Lipid Panel: To check cholesterol and triglyceride levels.
• Weight/BMI: Monitored at every visit.
• CBC (Complete Blood Count): To ensure white blood cell counts remain within a safe range.
• AIMS Exam: A physical assessment for involuntary movements.

Lurasidone can cause significant somnolence (drowsiness) and may impair judgment, thinking, and motor skills. Patients should not drive, operate heavy machinery, or engage in dangerous activities until they are certain the medication does not affect them in these ways.

Alcohol should be avoided while taking lurasidone. Alcohol can worsen the sedative effects of the medication and increase the risk of respiratory depression and impaired motor coordination.

If you and your doctor decide to stop lurasidone, the dose should be tapered (gradually reduced) rather than stopped suddenly. Abruptly stopping can cause 'rebound' psychosis or symptoms like nausea, sweating, and insomnia.

> Important: Discuss all your medical conditions, especially heart problems, diabetes, or a history of seizures, with your healthcare provider before starting Lurasidone.

Lurasidone is primarily broken down by the CYP3A4 enzyme in the liver. Therefore, any drug that strongly interferes with this enzyme will cause dangerous changes in lurasidone levels.

• Strong CYP3A4 Inhibitors: Drugs like ketoconazole, clarithromycin, and ritonavir can increase lurasidone levels by several hundred percent, leading to severe toxicity. Using these together is strictly contraindicated.
• Strong CYP3A4 Inducers: Drugs like rifampin, carbamazepine, and phenytoin can speed up the breakdown of lurasidone so much that it becomes completely ineffective. These combinations must be avoided.

• Moderate CYP3A4 Inhibitors: Examples include diltiazem, erythromycin, and verapamil. If these must be used, the dose of lurasidone should be reduced (typically to a maximum of 80 mg).
• Moderate CYP3A4 Inducers: Drugs like modafinil or bosentan may decrease lurasidone levels, requiring a potential dose increase of lurasidone.
• CNS Depressants: Taking lurasidone with other drugs that cause drowsiness—such as benzodiazepines (e.g., lorazepam), opioids, or certain sleep medications—can lead to extreme sedation and respiratory issues.

• Antihypertensive Agents: Because lurasidone can cause orthostatic hypotension (dizziness upon standing), taking it with blood pressure medications may increase the risk of fainting and falls.
• Dopamine Agonists: Drugs used for Parkinson’s disease (like levodopa) work by increasing dopamine, while lurasidone works by blocking it. These drugs can cancel each other out, worsening both conditions.

• Grapefruit and Grapefruit Juice: Grapefruit is a potent inhibitor of the CYP3A4 enzyme. Consuming grapefruit while taking lurasidone can lead to dangerously high levels of the drug in your system. It is best to avoid grapefruit products entirely.
• High-Calorie Requirement: As noted previously, lurasidone requires at least 350 calories for absorption. Failure to meet this requirement is a 'negative interaction' that results in sub-therapeutic drug levels.

• St. John’s Wort: This herbal supplement is a strong inducer of CYP3A4. Taking it with lurasidone can significantly reduce the medication's effectiveness, potentially leading to a relapse of psychiatric symptoms.
• Kava, Valerian, and Melatonin: These supplements have sedative properties and may increase the drowsiness caused by lurasidone.

Lurasidone does not typically interfere with common laboratory tests, but it can cause physiological changes that show up on labs, such as:

• False Positives for Urine Drug Screens: Some antipsychotics have been known to cause false positives for methadone or amphetamines, though this is less common with lurasidone than with other agents.
• Prolactin Elevation: Can be seen on hormone blood tests.

For each major interaction, the mechanism usually involves the liver's metabolic pathways. When lurasidone levels are too high, the clinical consequence is an increased risk of movement disorders and sedation. When levels are too low, the consequence is a lack of symptom control. Management strategies always involve dose titration or choosing alternative medications under strict medical supervision.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter cold medicines or vitamins.

There are specific circumstances where lurasidone must never be used due to the high risk of life-threatening complications.

1. 1Known Hypersensitivity: If a patient has had a previous severe allergic reaction to lurasidone hydrochloride or any of the inactive ingredients in the tablet (such as angioedema or severe rash), the drug is strictly contraindicated.
2. 2Strong CYP3A4 Inhibitors: Lurasidone must not be used in combination with strong inhibitors of the CYP3A4 enzyme (e.g., ketoconazole, clarithromycin, ritonavir). The mechanism is the inhibition of lurasidone's primary metabolic pathway, which can lead to a 6-fold to 9-fold increase in drug exposure, causing severe toxicity.
3. 3Strong CYP3A4 Inducers: Lurasidone must not be used with strong inducers of the CYP3A4 enzyme (e.g., rifampin, St. John's Wort, phenytoin). These substances cause the body to clear lurasidone so quickly that therapeutic levels cannot be maintained, rendering the treatment useless.

These are conditions where the drug should be used only if the benefits clearly outweigh the risks, and with extreme caution.

• Elderly Patients with Dementia: Due to the increased risk of death and stroke, lurasidone is generally avoided in this population unless no other options exist and the psychiatric symptoms are severe.
• Severe Hepatic or Renal Impairment: While not an absolute contraindication, these conditions require significant dose reductions and frequent monitoring.
• History of Seizures: Lurasidone can lower the threshold for seizures. It should be used cautiously in patients with epilepsy or conditions that predispose them to seizures (e.g., head trauma).
• Cardiovascular Disease: Patients with a history of heart attack, heart failure, or conduction abnormalities (like QT prolongation) require careful monitoring because lurasidone can cause orthostatic hypotension.

While lurasidone is chemically distinct, patients who have had severe reactions to other benzoisothiazol derivatives (such as ziprasidone) should be monitored closely, as there is a theoretical risk of cross-sensitivity, though this is not well-documented in clinical literature.

> Important: Your healthcare provider will evaluate your complete medical history, including any past reactions to psychiatric medications, before prescribing Lurasidone.

Lurasidone is classified by the FDA as a Pregnancy Category B medication (based on the older system), meaning animal studies have not shown a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

• Trimester-Specific Risks: During the third trimester, exposure to antipsychotic medications like lurasidone increases the risk of extrapyramidal symptoms (movement disorders) and withdrawal symptoms in the newborn after delivery. These symptoms can include agitation, hypertonia (increased muscle tone), hypotonia (decreased muscle tone), tremor, somnolence, and respiratory distress.
• Clinical Decision: Lurasidone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Stopping the medication during pregnancy can lead to a relapse of schizophrenia or bipolar depression, which also carries significant risks for both the mother and the baby.

It is not known whether lurasidone is excreted in human breast milk. However, animal studies have shown that lurasidone is present in the milk of lactating rats. Because of the potential for serious adverse reactions in nursing infants (such as sedation or movement issues), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Lurasidone is FDA-approved for:

• Schizophrenia: Children aged 13 to 17 years.
• Bipolar Depression: Children aged 10 to 17 years.

The safety and effectiveness of lurasidone in children under 10 years of age have not been established. In pediatric trials, the side effect profile was generally similar to that seen in adults, though there was a slightly higher incidence of weight gain and somnolence in younger patients.

Clinical studies of lurasidone did not include sufficient numbers of patients aged 65 and over to determine if they respond differently than younger patients. However, geriatric patients are generally more sensitive to the side effects of antipsychotics, particularly:

• Fall Risk: Due to sedation and orthostatic hypotension.
• Tardive Dyskinesia: Elderly women are at the highest risk for this movement disorder.
• Renal Clearance: Many elderly patients have reduced kidney function, which necessitates lower starting doses.

In patients with moderate (CrCl 30-50 mL/min) and severe (CrCl < 30 mL/min) renal impairment, the body's ability to clear lurasidone is reduced.

• Dose Adjustment: The starting dose should be 20 mg, and the dose should not exceed 80 mg per day. Lurasidone has not been extensively studied in patients on hemodialysis.

• Moderate Impairment (Child-Pugh 7-9): The dose should be capped at 80 mg.
• Severe Impairment (Child-Pugh 10-15): The dose should be capped at 40 mg.
• Mechanism: Since the liver is the primary site of metabolism, impairment leads to higher blood levels of the drug, increasing the risk of adverse effects.

> Important: Special populations require individualized medical assessment and frequent follow-up to ensure the medication remains safe and effective over time.

Lurasidone is an atypical antipsychotic with a unique binding profile. Its primary therapeutic effects are mediated through a combination of central dopamine D2 and serotonin 5-HT2A receptor antagonism.

• D2 Antagonism: By blocking dopamine D2 receptors in the mesolimbic pathway, lurasidone reduces the 'positive' symptoms of schizophrenia.
• 5-HT2A Antagonism: Blocking these serotonin receptors helps modulate dopamine release in other areas of the brain, potentially improving mood and reducing movement side effects.
• 5-HT7 Antagonism: Lurasidone has a very high affinity (Ki = 0.5 nM) for the 5-HT7 receptor. This is thought to contribute to its pro-cognitive and antidepressant effects.
• 5-HT1A Partial Agonism: Acts as a partial agonist (Ki = 6.4 nM) at this receptor, which may help alleviate anxiety and depressive symptoms.
• Minimal Off-Target Binding: It has low affinity for alpha-1 adrenergic receptors and almost no affinity for histamine H1 or muscarinic M1 receptors, explaining its lower incidence of weight gain and dry mouth.

The onset of action for lurasidone typically occurs within 1 to 2 weeks for initial symptom improvement, though the full therapeutic effect may take 4 to 6 weeks. It does not appear to cause significant QT prolongation (a heart rhythm issue) at therapeutic doses, which is a safety advantage over some other antipsychotics like ziprasidone.

| Parameter | Value |

|---|---|

| Bioavailability | 9% - 19% (Highly food-dependent) |

| Protein Binding | ~99% (Albumin and AAG) |

| Half-life | ~18 hours |

| Tmax | 1 - 3 hours |

| Metabolism | Hepatic (Primary CYP3A4) |

| Excretion | Fecal 80%, Renal 9% |

• Molecular Formula: C28H36N4O2S · HCl
• Molecular Weight: 529.14 g/mol
• Solubility: Very slightly soluble in water; soluble in methanol.
• Structure: It is a benzoisothiazol derivative characterized by a piperazine-based side chain and a bicyclic ring system.

Lurasidone is classified as an atypical (second-generation) antipsychotic. It is related to other medications in this class, such as aripiprazole, quetiapine, and risperidone, but is distinguished by its specific 5-HT7 receptor affinity and its metabolic-friendly profile.